Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Tema Heart & Health ETF (NQ:HRTS)

36.30 +0.06 (+0.16%)

Official Closing Price Updated: 4:15 PM EDT, Sep 25, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	505
Open	36.21
Bid (Size)	18.06 (200)
Ask (Size)	54.18 (200)
Prev. Close	36.24
Today's Range	36.21 - 36.30
52wk Range	29.54 - 38.87
Shares Outstanding	N/A
Dividend Yield	1.30%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing ↗

February 13, 2025

The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.

Via Stocktwits

Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes ↗

January 15, 2025

The company’s stock declined nearly 60% in 2024 and has lost an additional 21% in 2025, with this latest setback further dampening investor confidence.

Via Stocktwits

Performance

YTD	+2.6%	+2.6%
1 Month	-4.6%	-4.6%
3 Month	-0.9%	-0.9%
6 Month	+10.9%	+10.9%
1 Year	+21.1%	+21.1%

More News

EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss ↗

December 20, 2024

Via Benzinga

EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen' ↗

September 25, 2024

Via Benzinga

EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players' ↗

July 18, 2024

Via Benzinga

EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO ↗

July 07, 2024

Via Benzinga

What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients ↗

July 05, 2024

Via Investor's Business Daily

Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply ↗

May 29, 2024

Via Benzinga

Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test ↗

April 17, 2024

Via Investor's Business Daily

Healthcare ETFs For The Weight-Loss Drug Boom And Beyond ↗

April 08, 2024

Via Talk Markets

Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On. ↗

February 23, 2024

Via Investor's Business Daily

Ozempic, Weygovy – Obesity And Heart Health Constitute A Major Market That Is Only Growing ↗

January 29, 2024

Via Benzinga

Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market ↗

December 04, 2023

Via Benzinga

EXCLUSIVE: Tema ETFs' Innovative Thematic Investing Approach Targets New Opportunities Beyond The Fads ↗

December 01, 2023

Via Benzinga

Frequently Asked Questions

Is Tema Heart & Health ETF publicly traded?

Yes, Tema Heart & Health ETF is publicly traded.

What exchange does Tema Heart & Health ETF trade on?

Tema Heart & Health ETF trades on the Nasdaq Stock Market

What is the ticker symbol for Tema Heart & Health ETF?

The ticker symbol for Tema Heart & Health ETF is HRTS on the Nasdaq Stock Market

What is the current price of Tema Heart & Health ETF?

The current price of Tema Heart & Health ETF is 36.30

When was Tema Heart & Health ETF last traded?

The last trade of Tema Heart & Health ETF was at 09/25/26 04:15 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.